Invasive meningococcal disease is predominantly caused by serogroups A, B, C, Y and W-135 worldwide.

Shanghai Mental Health Center (SMHC) has selected Signant Health to provide electronic informed consent for a neuroscience study on schizophrenia.

The investigator-led trial will enrol patients at different sites in the country and will use Signant’s TrialConsent solution.

TrialConsent will use knowledge quizzes, multimedia videos, self-paced content review and other eConsent methods to help patients and their families understand the risks, benefits and expectations before enrolling in the study.

The platform will benefit the trial as the patients will be engaged. This will result in better retention of patients throughout the duration of the study, Signant Health said.

SMHC will also receive a real-time review of patient compliance and consent data and automated document management, thereby avoiding most consent-related audit findings.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

SHMC Department of Psychology vice-director Dr Shen said: “SMHC was confident Signant could support the large-scale investigator-led study involving several hundred subjects across numerous hospital sites, generating significant data. Robust data collection is critical and patient-centric digitisation of the eConsent process will deliver enormous benefit to all stakeholders in this important study.”

Signant CEO Mike Nolte said: “Signant Health’s growing work in Asia supports accelerating demand from life science companies and academic partners in this region for the pioneering services we provide, our deep therapeutic area expertise, scientific and clinical consulting, and data quality analytics that leverage technology to transform the quality and impact of their research studies.”

SMHC is affiliated to the Shanghai Jiao Tong University, research university in China which works on mental health prevention.

Last month, Signant Health launched a new partner programme to collaborate with clinical research organisations (CROs) in a bid to improve clinical trials with patient-centric technology.

CRF Bracket, which was formed as a merged entity of CRF Health and Bracket, was launched as Signant Health in June.